PMC:7341831 / 7414-8863 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T32","span":{"begin":326,"end":332},"obj":"Body_part"},{"id":"T33","span":{"begin":625,"end":629},"obj":"Body_part"},{"id":"T34","span":{"begin":712,"end":726},"obj":"Body_part"},{"id":"T36","span":{"begin":812,"end":827},"obj":"Body_part"},{"id":"T37","span":{"begin":857,"end":861},"obj":"Body_part"},{"id":"T38","span":{"begin":882,"end":890},"obj":"Body_part"},{"id":"T39","span":{"begin":1001,"end":1014},"obj":"Body_part"},{"id":"T40","span":{"begin":1001,"end":1006},"obj":"Body_part"},{"id":"T41","span":{"begin":1287,"end":1292},"obj":"Body_part"}],"attributes":[{"id":"A32","pred":"fma_id","subj":"T32","obj":"http://purl.org/sig/ont/fma/fma7203"},{"id":"A33","pred":"fma_id","subj":"T33","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A34","pred":"fma_id","subj":"T34","obj":"http://purl.org/sig/ont/fma/fma13121"},{"id":"A35","pred":"fma_id","subj":"T34","obj":"http://purl.org/sig/ont/fma/fma67480"},{"id":"A36","pred":"fma_id","subj":"T36","obj":"http://purl.org/sig/ont/fma/fma27360"},{"id":"A37","pred":"fma_id","subj":"T37","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A38","pred":"fma_id","subj":"T38","obj":"http://purl.org/sig/ont/fma/fma264783"},{"id":"A39","pred":"fma_id","subj":"T39","obj":"http://purl.org/sig/ont/fma/fma63183"},{"id":"A40","pred":"fma_id","subj":"T40","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A41","pred":"fma_id","subj":"T41","obj":"http://purl.org/sig/ont/fma/fma9670"}],"text":"Our report illustrates the importance of considering IPA in patients with underlying severe COVID-19, who show no clear clinical impairment related to IPA throughout their hospitalization. In this case, the patient was likely immunologically compromised due to his underlying conditions (Type II diabetes mellitus and chronic kidney disease). This case underscores the need to investigate this neglected disease and allow for early tracing with antifungal treatment; however, it is necessary to consider the risks posed by the bronchoscopy that must be performed for the diagnosis. Antinori et al. 8 assessed the postmortem lung examination of a patient with IPA and COVID-19, in which IPA was characterized by bronchial wall ulceration associated with multiple spots of necrotizing pneumonia, and the residual lung parenchyma displayed a pattern of acute lung injury with diffuse alveolar damage. In addition to the presence of bronchopneumonia, we distinctly show fungi (hyphae and conidia) within blood vessels, the hallmark of the invasive disease triggered by this fungus. The presence of GM in bronchoalveolar lavage is a useful marker, but this procedure is not performed in many COVID-19 patients for biosafety reasons. However, the identification of this antigen in peripheral blood, a test that is usually negative, is seemingly a reliable marker of invasive disease, especially in our case, in which the invasion of vessels was observed."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T21","span":{"begin":326,"end":332},"obj":"Body_part"},{"id":"T22","span":{"begin":625,"end":629},"obj":"Body_part"},{"id":"T23","span":{"begin":812,"end":827},"obj":"Body_part"},{"id":"T24","span":{"begin":812,"end":816},"obj":"Body_part"},{"id":"T25","span":{"begin":817,"end":827},"obj":"Body_part"},{"id":"T26","span":{"begin":857,"end":861},"obj":"Body_part"},{"id":"T27","span":{"begin":1001,"end":1014},"obj":"Body_part"},{"id":"T28","span":{"begin":1001,"end":1006},"obj":"Body_part"},{"id":"T29","span":{"begin":1007,"end":1014},"obj":"Body_part"},{"id":"T30","span":{"begin":1287,"end":1292},"obj":"Body_part"},{"id":"T31","span":{"begin":1428,"end":1435},"obj":"Body_part"}],"attributes":[{"id":"A21","pred":"uberon_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"A22","pred":"uberon_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A23","pred":"uberon_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/UBERON_0008946"},{"id":"A24","pred":"uberon_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A25","pred":"uberon_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/UBERON_0000353"},{"id":"A26","pred":"uberon_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A27","pred":"uberon_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/UBERON_0001981"},{"id":"A28","pred":"uberon_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A29","pred":"uberon_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/UBERON_0000055"},{"id":"A30","pred":"uberon_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A31","pred":"uberon_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/UBERON_0000055"}],"text":"Our report illustrates the importance of considering IPA in patients with underlying severe COVID-19, who show no clear clinical impairment related to IPA throughout their hospitalization. In this case, the patient was likely immunologically compromised due to his underlying conditions (Type II diabetes mellitus and chronic kidney disease). This case underscores the need to investigate this neglected disease and allow for early tracing with antifungal treatment; however, it is necessary to consider the risks posed by the bronchoscopy that must be performed for the diagnosis. Antinori et al. 8 assessed the postmortem lung examination of a patient with IPA and COVID-19, in which IPA was characterized by bronchial wall ulceration associated with multiple spots of necrotizing pneumonia, and the residual lung parenchyma displayed a pattern of acute lung injury with diffuse alveolar damage. In addition to the presence of bronchopneumonia, we distinctly show fungi (hyphae and conidia) within blood vessels, the hallmark of the invasive disease triggered by this fungus. The presence of GM in bronchoalveolar lavage is a useful marker, but this procedure is not performed in many COVID-19 patients for biosafety reasons. However, the identification of this antigen in peripheral blood, a test that is usually negative, is seemingly a reliable marker of invasive disease, especially in our case, in which the invasion of vessels was observed."}

{"project":"LitCovid-PubTator","denotations":[{"id":"196","span":{"begin":60,"end":68},"obj":"Species"},{"id":"197","span":{"begin":207,"end":214},"obj":"Species"},{"id":"198","span":{"begin":647,"end":654},"obj":"Species"},{"id":"199","span":{"begin":1197,"end":1205},"obj":"Species"},{"id":"200","span":{"begin":1095,"end":1097},"obj":"Chemical"},{"id":"201","span":{"begin":92,"end":100},"obj":"Disease"},{"id":"202","span":{"begin":288,"end":313},"obj":"Disease"},{"id":"203","span":{"begin":318,"end":340},"obj":"Disease"},{"id":"204","span":{"begin":668,"end":676},"obj":"Disease"},{"id":"205","span":{"begin":772,"end":793},"obj":"Disease"},{"id":"206","span":{"begin":857,"end":868},"obj":"Disease"},{"id":"207","span":{"begin":882,"end":897},"obj":"Disease"},{"id":"208","span":{"begin":930,"end":946},"obj":"Disease"},{"id":"209","span":{"begin":1020,"end":1052},"obj":"Disease"},{"id":"210","span":{"begin":1188,"end":1196},"obj":"Disease"},{"id":"211","span":{"begin":1361,"end":1377},"obj":"Disease"}],"attributes":[{"id":"A196","pred":"tao:has_database_id","subj":"196","obj":"Tax:9606"},{"id":"A197","pred":"tao:has_database_id","subj":"197","obj":"Tax:9606"},{"id":"A198","pred":"tao:has_database_id","subj":"198","obj":"Tax:9606"},{"id":"A199","pred":"tao:has_database_id","subj":"199","obj":"Tax:9606"},{"id":"A200","pred":"tao:has_database_id","subj":"200","obj":"MESH:C012990"},{"id":"A201","pred":"tao:has_database_id","subj":"201","obj":"MESH:C000657245"},{"id":"A202","pred":"tao:has_database_id","subj":"202","obj":"MESH:D003924"},{"id":"A203","pred":"tao:has_database_id","subj":"203","obj":"MESH:D051436"},{"id":"A204","pred":"tao:has_database_id","subj":"204","obj":"MESH:C000657245"},{"id":"A205","pred":"tao:has_database_id","subj":"205","obj":"MESH:D011014"},{"id":"A206","pred":"tao:has_database_id","subj":"206","obj":"MESH:D055370"},{"id":"A207","pred":"tao:has_database_id","subj":"207","obj":"MESH:D055370"},{"id":"A208","pred":"tao:has_database_id","subj":"208","obj":"MESH:D001996"},{"id":"A209","pred":"tao:has_database_id","subj":"209","obj":"MESH:D009361"},{"id":"A210","pred":"tao:has_database_id","subj":"210","obj":"MESH:C000657245"},{"id":"A211","pred":"tao:has_database_id","subj":"211","obj":"MESH:D009361"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Our report illustrates the importance of considering IPA in patients with underlying severe COVID-19, who show no clear clinical impairment related to IPA throughout their hospitalization. In this case, the patient was likely immunologically compromised due to his underlying conditions (Type II diabetes mellitus and chronic kidney disease). This case underscores the need to investigate this neglected disease and allow for early tracing with antifungal treatment; however, it is necessary to consider the risks posed by the bronchoscopy that must be performed for the diagnosis. Antinori et al. 8 assessed the postmortem lung examination of a patient with IPA and COVID-19, in which IPA was characterized by bronchial wall ulceration associated with multiple spots of necrotizing pneumonia, and the residual lung parenchyma displayed a pattern of acute lung injury with diffuse alveolar damage. In addition to the presence of bronchopneumonia, we distinctly show fungi (hyphae and conidia) within blood vessels, the hallmark of the invasive disease triggered by this fungus. The presence of GM in bronchoalveolar lavage is a useful marker, but this procedure is not performed in many COVID-19 patients for biosafety reasons. However, the identification of this antigen in peripheral blood, a test that is usually negative, is seemingly a reliable marker of invasive disease, especially in our case, in which the invasion of vessels was observed."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T54","span":{"begin":92,"end":100},"obj":"Disease"},{"id":"T55","span":{"begin":288,"end":313},"obj":"Disease"},{"id":"T56","span":{"begin":296,"end":313},"obj":"Disease"},{"id":"T57","span":{"begin":318,"end":340},"obj":"Disease"},{"id":"T58","span":{"begin":326,"end":340},"obj":"Disease"},{"id":"T60","span":{"begin":668,"end":676},"obj":"Disease"},{"id":"T61","span":{"begin":727,"end":737},"obj":"Disease"},{"id":"T62","span":{"begin":784,"end":793},"obj":"Disease"},{"id":"T63","span":{"begin":851,"end":868},"obj":"Disease"},{"id":"T65","span":{"begin":862,"end":868},"obj":"Disease"},{"id":"T66","span":{"begin":930,"end":946},"obj":"Disease"},{"id":"T67","span":{"begin":1188,"end":1196},"obj":"Disease"}],"attributes":[{"id":"A54","pred":"mondo_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A55","pred":"mondo_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/MONDO_0005148"},{"id":"A56","pred":"mondo_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"},{"id":"A57","pred":"mondo_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/MONDO_0005300"},{"id":"A58","pred":"mondo_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/MONDO_0001343"},{"id":"A59","pred":"mondo_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/MONDO_0005240"},{"id":"A60","pred":"mondo_id","subj":"T60","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A61","pred":"mondo_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/MONDO_0043839"},{"id":"A62","pred":"mondo_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A63","pred":"mondo_id","subj":"T63","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A64","pred":"mondo_id","subj":"T63","obj":"http://purl.obolibrary.org/obo/MONDO_0015796"},{"id":"A65","pred":"mondo_id","subj":"T65","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A66","pred":"mondo_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/MONDO_0005682"},{"id":"A67","pred":"mondo_id","subj":"T67","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Our report illustrates the importance of considering IPA in patients with underlying severe COVID-19, who show no clear clinical impairment related to IPA throughout their hospitalization. In this case, the patient was likely immunologically compromised due to his underlying conditions (Type II diabetes mellitus and chronic kidney disease). This case underscores the need to investigate this neglected disease and allow for early tracing with antifungal treatment; however, it is necessary to consider the risks posed by the bronchoscopy that must be performed for the diagnosis. Antinori et al. 8 assessed the postmortem lung examination of a patient with IPA and COVID-19, in which IPA was characterized by bronchial wall ulceration associated with multiple spots of necrotizing pneumonia, and the residual lung parenchyma displayed a pattern of acute lung injury with diffuse alveolar damage. In addition to the presence of bronchopneumonia, we distinctly show fungi (hyphae and conidia) within blood vessels, the hallmark of the invasive disease triggered by this fungus. The presence of GM in bronchoalveolar lavage is a useful marker, but this procedure is not performed in many COVID-19 patients for biosafety reasons. However, the identification of this antigen in peripheral blood, a test that is usually negative, is seemingly a reliable marker of invasive disease, especially in our case, in which the invasion of vessels was observed."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T56","span":{"begin":326,"end":332},"obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"T57","span":{"begin":326,"end":332},"obj":"http://www.ebi.ac.uk/efo/EFO_0000927"},{"id":"T58","span":{"begin":326,"end":332},"obj":"http://www.ebi.ac.uk/efo/EFO_0000929"},{"id":"T59","span":{"begin":625,"end":629},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T60","span":{"begin":625,"end":629},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T61","span":{"begin":645,"end":646},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T62","span":{"begin":812,"end":816},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T63","span":{"begin":812,"end":816},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T64","span":{"begin":838,"end":839},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T65","span":{"begin":857,"end":861},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T66","span":{"begin":857,"end":861},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T67","span":{"begin":1001,"end":1014},"obj":"http://purl.obolibrary.org/obo/UBERON_0001981"},{"id":"T68","span":{"begin":1001,"end":1014},"obj":"http://www.ebi.ac.uk/efo/EFO_0000817"},{"id":"T69","span":{"begin":1127,"end":1128},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T70","span":{"begin":1287,"end":1292},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T71","span":{"begin":1287,"end":1292},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T72","span":{"begin":1294,"end":1295},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T73","span":{"begin":1296,"end":1300},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T74","span":{"begin":1340,"end":1341},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T75","span":{"begin":1428,"end":1435},"obj":"http://purl.obolibrary.org/obo/UBERON_0000055"}],"text":"Our report illustrates the importance of considering IPA in patients with underlying severe COVID-19, who show no clear clinical impairment related to IPA throughout their hospitalization. In this case, the patient was likely immunologically compromised due to his underlying conditions (Type II diabetes mellitus and chronic kidney disease). This case underscores the need to investigate this neglected disease and allow for early tracing with antifungal treatment; however, it is necessary to consider the risks posed by the bronchoscopy that must be performed for the diagnosis. Antinori et al. 8 assessed the postmortem lung examination of a patient with IPA and COVID-19, in which IPA was characterized by bronchial wall ulceration associated with multiple spots of necrotizing pneumonia, and the residual lung parenchyma displayed a pattern of acute lung injury with diffuse alveolar damage. In addition to the presence of bronchopneumonia, we distinctly show fungi (hyphae and conidia) within blood vessels, the hallmark of the invasive disease triggered by this fungus. The presence of GM in bronchoalveolar lavage is a useful marker, but this procedure is not performed in many COVID-19 patients for biosafety reasons. However, the identification of this antigen in peripheral blood, a test that is usually negative, is seemingly a reliable marker of invasive disease, especially in our case, in which the invasion of vessels was observed."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T62","span":{"begin":53,"end":56},"obj":"Chemical"},{"id":"T64","span":{"begin":151,"end":154},"obj":"Chemical"},{"id":"T66","span":{"begin":293,"end":295},"obj":"Chemical"},{"id":"T67","span":{"begin":445,"end":455},"obj":"Chemical"},{"id":"T68","span":{"begin":660,"end":663},"obj":"Chemical"},{"id":"T70","span":{"begin":687,"end":690},"obj":"Chemical"},{"id":"T72","span":{"begin":1095,"end":1097},"obj":"Chemical"},{"id":"T74","span":{"begin":1265,"end":1272},"obj":"Chemical"}],"attributes":[{"id":"A62","pred":"chebi_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A63","pred":"chebi_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"},{"id":"A64","pred":"chebi_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A65","pred":"chebi_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"},{"id":"A66","pred":"chebi_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A67","pred":"chebi_id","subj":"T67","obj":"http://purl.obolibrary.org/obo/CHEBI_35718"},{"id":"A68","pred":"chebi_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A69","pred":"chebi_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"},{"id":"A70","pred":"chebi_id","subj":"T70","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A71","pred":"chebi_id","subj":"T70","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"},{"id":"A72","pred":"chebi_id","subj":"T72","obj":"http://purl.obolibrary.org/obo/CHEBI_74120"},{"id":"A73","pred":"chebi_id","subj":"T72","obj":"http://purl.obolibrary.org/obo/CHEBI_27680"},{"id":"A74","pred":"chebi_id","subj":"T74","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"}],"text":"Our report illustrates the importance of considering IPA in patients with underlying severe COVID-19, who show no clear clinical impairment related to IPA throughout their hospitalization. In this case, the patient was likely immunologically compromised due to his underlying conditions (Type II diabetes mellitus and chronic kidney disease). This case underscores the need to investigate this neglected disease and allow for early tracing with antifungal treatment; however, it is necessary to consider the risks posed by the bronchoscopy that must be performed for the diagnosis. Antinori et al. 8 assessed the postmortem lung examination of a patient with IPA and COVID-19, in which IPA was characterized by bronchial wall ulceration associated with multiple spots of necrotizing pneumonia, and the residual lung parenchyma displayed a pattern of acute lung injury with diffuse alveolar damage. In addition to the presence of bronchopneumonia, we distinctly show fungi (hyphae and conidia) within blood vessels, the hallmark of the invasive disease triggered by this fungus. The presence of GM in bronchoalveolar lavage is a useful marker, but this procedure is not performed in many COVID-19 patients for biosafety reasons. However, the identification of this antigen in peripheral blood, a test that is usually negative, is seemingly a reliable marker of invasive disease, especially in our case, in which the invasion of vessels was observed."}

{"project":"LitCovid-PD-GlycoEpitope","denotations":[{"id":"T6","span":{"begin":1095,"end":1097},"obj":"GlycoEpitope"}],"attributes":[{"id":"A6","pred":"glyco_epitope_db_id","subj":"T6","obj":"http://www.glycoepitope.jp/epitopes/EP0510"}],"text":"Our report illustrates the importance of considering IPA in patients with underlying severe COVID-19, who show no clear clinical impairment related to IPA throughout their hospitalization. In this case, the patient was likely immunologically compromised due to his underlying conditions (Type II diabetes mellitus and chronic kidney disease). This case underscores the need to investigate this neglected disease and allow for early tracing with antifungal treatment; however, it is necessary to consider the risks posed by the bronchoscopy that must be performed for the diagnosis. Antinori et al. 8 assessed the postmortem lung examination of a patient with IPA and COVID-19, in which IPA was characterized by bronchial wall ulceration associated with multiple spots of necrotizing pneumonia, and the residual lung parenchyma displayed a pattern of acute lung injury with diffuse alveolar damage. In addition to the presence of bronchopneumonia, we distinctly show fungi (hyphae and conidia) within blood vessels, the hallmark of the invasive disease triggered by this fungus. The presence of GM in bronchoalveolar lavage is a useful marker, but this procedure is not performed in many COVID-19 patients for biosafety reasons. However, the identification of this antigen in peripheral blood, a test that is usually negative, is seemingly a reliable marker of invasive disease, especially in our case, in which the invasion of vessels was observed."}

{"project":"LitCovid-sentences","denotations":[{"id":"T73","span":{"begin":0,"end":188},"obj":"Sentence"},{"id":"T74","span":{"begin":189,"end":342},"obj":"Sentence"},{"id":"T75","span":{"begin":343,"end":581},"obj":"Sentence"},{"id":"T76","span":{"begin":582,"end":597},"obj":"Sentence"},{"id":"T77","span":{"begin":598,"end":898},"obj":"Sentence"},{"id":"T78","span":{"begin":899,"end":1078},"obj":"Sentence"},{"id":"T79","span":{"begin":1079,"end":1228},"obj":"Sentence"},{"id":"T80","span":{"begin":1229,"end":1449},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Our report illustrates the importance of considering IPA in patients with underlying severe COVID-19, who show no clear clinical impairment related to IPA throughout their hospitalization. In this case, the patient was likely immunologically compromised due to his underlying conditions (Type II diabetes mellitus and chronic kidney disease). This case underscores the need to investigate this neglected disease and allow for early tracing with antifungal treatment; however, it is necessary to consider the risks posed by the bronchoscopy that must be performed for the diagnosis. Antinori et al. 8 assessed the postmortem lung examination of a patient with IPA and COVID-19, in which IPA was characterized by bronchial wall ulceration associated with multiple spots of necrotizing pneumonia, and the residual lung parenchyma displayed a pattern of acute lung injury with diffuse alveolar damage. In addition to the presence of bronchopneumonia, we distinctly show fungi (hyphae and conidia) within blood vessels, the hallmark of the invasive disease triggered by this fungus. The presence of GM in bronchoalveolar lavage is a useful marker, but this procedure is not performed in many COVID-19 patients for biosafety reasons. However, the identification of this antigen in peripheral blood, a test that is usually negative, is seemingly a reliable marker of invasive disease, especially in our case, in which the invasion of vessels was observed."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T25","span":{"begin":53,"end":56},"obj":"Phenotype"},{"id":"T26","span":{"begin":151,"end":154},"obj":"Phenotype"},{"id":"T27","span":{"begin":288,"end":313},"obj":"Phenotype"},{"id":"T28","span":{"begin":318,"end":340},"obj":"Phenotype"},{"id":"T29","span":{"begin":660,"end":663},"obj":"Phenotype"},{"id":"T30","span":{"begin":687,"end":690},"obj":"Phenotype"},{"id":"T31","span":{"begin":784,"end":793},"obj":"Phenotype"},{"id":"T32","span":{"begin":851,"end":868},"obj":"Phenotype"},{"id":"T33","span":{"begin":874,"end":897},"obj":"Phenotype"}],"attributes":[{"id":"A25","pred":"hp_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/HP_0020103"},{"id":"A26","pred":"hp_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/HP_0020103"},{"id":"A27","pred":"hp_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/HP_0005978"},{"id":"A28","pred":"hp_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/HP_0012622"},{"id":"A29","pred":"hp_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/HP_0020103"},{"id":"A30","pred":"hp_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/HP_0020103"},{"id":"A31","pred":"hp_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A32","pred":"hp_id","subj":"T32","obj":"http://www.orpha.net/ORDO/Orphanet_178320"},{"id":"A33","pred":"hp_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/HP_0033006"}],"text":"Our report illustrates the importance of considering IPA in patients with underlying severe COVID-19, who show no clear clinical impairment related to IPA throughout their hospitalization. In this case, the patient was likely immunologically compromised due to his underlying conditions (Type II diabetes mellitus and chronic kidney disease). This case underscores the need to investigate this neglected disease and allow for early tracing with antifungal treatment; however, it is necessary to consider the risks posed by the bronchoscopy that must be performed for the diagnosis. Antinori et al. 8 assessed the postmortem lung examination of a patient with IPA and COVID-19, in which IPA was characterized by bronchial wall ulceration associated with multiple spots of necrotizing pneumonia, and the residual lung parenchyma displayed a pattern of acute lung injury with diffuse alveolar damage. In addition to the presence of bronchopneumonia, we distinctly show fungi (hyphae and conidia) within blood vessels, the hallmark of the invasive disease triggered by this fungus. The presence of GM in bronchoalveolar lavage is a useful marker, but this procedure is not performed in many COVID-19 patients for biosafety reasons. However, the identification of this antigen in peripheral blood, a test that is usually negative, is seemingly a reliable marker of invasive disease, especially in our case, in which the invasion of vessels was observed."}

{"project":"2_test","denotations":[{"id":"32638890-32470620-134289068","span":{"begin":598,"end":599},"obj":"32470620"}],"text":"Our report illustrates the importance of considering IPA in patients with underlying severe COVID-19, who show no clear clinical impairment related to IPA throughout their hospitalization. In this case, the patient was likely immunologically compromised due to his underlying conditions (Type II diabetes mellitus and chronic kidney disease). This case underscores the need to investigate this neglected disease and allow for early tracing with antifungal treatment; however, it is necessary to consider the risks posed by the bronchoscopy that must be performed for the diagnosis. Antinori et al. 8 assessed the postmortem lung examination of a patient with IPA and COVID-19, in which IPA was characterized by bronchial wall ulceration associated with multiple spots of necrotizing pneumonia, and the residual lung parenchyma displayed a pattern of acute lung injury with diffuse alveolar damage. In addition to the presence of bronchopneumonia, we distinctly show fungi (hyphae and conidia) within blood vessels, the hallmark of the invasive disease triggered by this fungus. The presence of GM in bronchoalveolar lavage is a useful marker, but this procedure is not performed in many COVID-19 patients for biosafety reasons. However, the identification of this antigen in peripheral blood, a test that is usually negative, is seemingly a reliable marker of invasive disease, especially in our case, in which the invasion of vessels was observed."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T133","span":{"begin":92,"end":100},"obj":"SP_7"},{"id":"T134","span":{"begin":326,"end":332},"obj":"UBERON:0002113"},{"id":"T135","span":{"begin":614,"end":624},"obj":"GO:0016265"},{"id":"T136","span":{"begin":625,"end":629},"obj":"UBERON:0002048"},{"id":"T137","span":{"begin":668,"end":676},"obj":"SP_7"},{"id":"T138","span":{"begin":712,"end":721},"obj":"UBERON:0004242"},{"id":"T139","span":{"begin":722,"end":726},"obj":"UBERON:0000060"},{"id":"T140","span":{"begin":812,"end":827},"obj":"UBERON:0008946"},{"id":"T141","span":{"begin":857,"end":861},"obj":"UBERON:0002048"},{"id":"T142","span":{"begin":882,"end":890},"obj":"UBERON:0003215"},{"id":"T143","span":{"begin":967,"end":972},"obj":"NCBITaxon:4751"},{"id":"T144","span":{"begin":1001,"end":1014},"obj":"UBERON:0001981"},{"id":"T145","span":{"begin":1071,"end":1077},"obj":"NCBITaxon:4751"},{"id":"T146","span":{"begin":1101,"end":1116},"obj":"UBERON:0002186"},{"id":"T147","span":{"begin":1188,"end":1196},"obj":"SP_7"},{"id":"T148","span":{"begin":1265,"end":1272},"obj":"CHEBI:59132;CHEBI:59132"},{"id":"T149","span":{"begin":1287,"end":1292},"obj":"UBERON:0000178"},{"id":"T150","span":{"begin":1428,"end":1435},"obj":"UBERON:0000055"},{"id":"T82423","span":{"begin":92,"end":100},"obj":"SP_7"},{"id":"T34071","span":{"begin":326,"end":332},"obj":"UBERON:0002113"},{"id":"T61699","span":{"begin":614,"end":624},"obj":"GO:0016265"},{"id":"T93941","span":{"begin":625,"end":629},"obj":"UBERON:0002048"},{"id":"T73256","span":{"begin":668,"end":676},"obj":"SP_7"},{"id":"T83346","span":{"begin":712,"end":721},"obj":"UBERON:0004242"},{"id":"T74144","span":{"begin":722,"end":726},"obj":"UBERON:0000060"},{"id":"T44419","span":{"begin":812,"end":827},"obj":"UBERON:0008946"},{"id":"T67181","span":{"begin":857,"end":861},"obj":"UBERON:0002048"},{"id":"T79335","span":{"begin":882,"end":890},"obj":"UBERON:0003215"},{"id":"T86622","span":{"begin":967,"end":972},"obj":"NCBITaxon:4751"},{"id":"T73261","span":{"begin":1001,"end":1014},"obj":"UBERON:0001981"},{"id":"T66563","span":{"begin":1071,"end":1077},"obj":"NCBITaxon:4751"},{"id":"T54734","span":{"begin":1101,"end":1116},"obj":"UBERON:0002186"},{"id":"T1262","span":{"begin":1188,"end":1196},"obj":"SP_7"},{"id":"T38840","span":{"begin":1265,"end":1272},"obj":"CHEBI:59132;CHEBI:59132"},{"id":"T52237","span":{"begin":1287,"end":1292},"obj":"UBERON:0000178"},{"id":"T44074","span":{"begin":1428,"end":1435},"obj":"UBERON:0000055"}],"text":"Our report illustrates the importance of considering IPA in patients with underlying severe COVID-19, who show no clear clinical impairment related to IPA throughout their hospitalization. In this case, the patient was likely immunologically compromised due to his underlying conditions (Type II diabetes mellitus and chronic kidney disease). This case underscores the need to investigate this neglected disease and allow for early tracing with antifungal treatment; however, it is necessary to consider the risks posed by the bronchoscopy that must be performed for the diagnosis. Antinori et al. 8 assessed the postmortem lung examination of a patient with IPA and COVID-19, in which IPA was characterized by bronchial wall ulceration associated with multiple spots of necrotizing pneumonia, and the residual lung parenchyma displayed a pattern of acute lung injury with diffuse alveolar damage. In addition to the presence of bronchopneumonia, we distinctly show fungi (hyphae and conidia) within blood vessels, the hallmark of the invasive disease triggered by this fungus. The presence of GM in bronchoalveolar lavage is a useful marker, but this procedure is not performed in many COVID-19 patients for biosafety reasons. However, the identification of this antigen in peripheral blood, a test that is usually negative, is seemingly a reliable marker of invasive disease, especially in our case, in which the invasion of vessels was observed."}